The U.S. Food and Drug Administration approved MorphoSys and Incyte’s Monjuvi (tafasitamab-cxix) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.
Boehringer Ingelheim and Eli Lilly announced that the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, met the primary endpoint.
Bristol Myers Squibb and bluebird bio announced the submission of their Biologics License Application (BLA) to the U.S. Food and Drug Administration for idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma.
The U.S. Food and Drug Administration approved GlaxoSmithKline Plc’s HIV drug Rukobia to treat adult patients who have run out of treatment options.
The death toll from COVID-19 surpassed half a million people, according to a Reuters tally, a grim milestone for the global pandemic that seems to be resurgent in some countries even as other regions are still grappling with the first wave.
Merck’s investigational pneumonia vaccine V114 hit the mark in two Phase III studies, including one involving adult HIV patients.
Shares of Epizyme stock rose after the company’s first-in-class EZH2 inhibitor Tazverik won approval from the U.S. Food and Drug Administration for the second time in 2020.
Merck’s vaunted checkpoint inhibitor Keytruda won U.S. approval for a new indication.
The U.S. Food and Drug Administration approved Viela Bio’s Uplizna (inebilizumab-cdon) for adults with neuromyelitis optica spectrum disorder who are anti-AQP4 antibody positive.
Children have milder COVID-19 symptoms than adults and the balance of evidence suggests they may also have lower susceptibility and infectivity than adults, scientists advising the British government said.